Printer Friendly
The Free Library
19,604,530 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Arrhythmia Research Technology, Inc. S-3 Registration Statement Declared Effective by SEC.


FITCHBURG, Mass. -- Arrhythmia arrhythmia (ārĭth`mēə), disturbance in the rate or rhythm of the heartbeat. Various arrhythmias can be symptoms of serious heart disorders; however, they are usually of no medical significance except in the presence of  Research Technology, Inc. ("Company") today announced that the shelf registration statement on Form S-3 originally filed with the Securities and Exchange Commission on May 6, 2004 as thereafter amended has been declared effective. The registration statement covers 500,000 shares of the Company's common stock and will permit the Company to offer and sell the shares, from time to time. There are no immediate plans to offer and sell the registered shares. The Company believes that the shelf registration statement will afford greater flexibility in accessing capital markets when market conditions are conducive to an offering. Any proceeds from such a sale will be used to acquire or invest in businesses, products and technologies or other opportunities providing accretive earnings and increasing shareholder value.

The Company, through Micron, produces silver plated sensors and distributes metal snaps for manufacturers of disposable ECG ECG electrocardiogram.

ECG
abbr.
1. electrocardiogram

2. electrocardiograph


ECG
Also called an electrocardiogram, it records the electrical activity of the heart.
 electrodes and through Micron's NEM division manufactures injection molded products for medical, electronics, industrial and consumer applications. The Company's products also include proprietary signal-averaging electrocardiographic electrocardiographic

emanating from or pertaining to electrocardiography.


electrocardiographic monitoring
maintenance of a more or less continuous surveillance of a patient's cardiac status by means of electrocardiography.
 (SAECG SAECG Signal-Averaged Electrocardiogram ) software used in the detection and treatment of potentially lethal heart arrhythmias.

Forward-looking statements forward-looking statement

A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections.
 made herein are based on current expectations of ART and involve a number of risks and uncertainties and should not be considered as guarantees of future performance. The factors that could cause actual results to differ materially include: interruptions or cancellations of existing contracts, impact of competitive products and pricing, product demand and market acceptance, risks, the presence of competitors with greater financial resources than ART, product development and commercialization risks, changing economic conditions in developing countries, and an inability to arrange additional debt or equity financing Equity Financing

The act of raising money for company activities by selling common or preferred stock to individual or institutional investors. In return for the money paid, shareholders receive ownership interests in the corporation.
.
COPYRIGHT 2004 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Sep 15, 2004
Words:271
Previous Article:Reckson Announces Common Stock Offering of 5.0 Million Shares.
Next Article:Free Online Energy Classroom Launched by Xcel Energy.
Topics:



Related Articles
Arrhythmia Research Technology, Inc. Makes Announcement.
Del Global Technologies Receives Relief from SEC Relating to Selected Financial Data; Receipt of Relief Allows Del to Commence Other Corporate...
ALARIS Medical Inc. Announces Shelf Registration.
Clinical Data Files Form S-3 Shelf Registration for 2,672,500 Shares of Common Stock.
Conseco, Inc. Files Registration Statement.
Dyax Files Shelf Registration Statement.
Plum Creek Files Shelf Registration.
Sanswire Technologies Announces Registration.
AVANIR Pharmaceuticals Files Shelf Registration Statement.
Endologix Files Shelf Registration Statement.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles